C omposition for preventing or treating sjogren's syndrome comprising PAX3

摘要

The present invention identified the potential of PAX3 as a new therapeutic agent to effectively treat Sjogren's syndrome. It was found that overexpression of PAX3 in an animal model induced with Sjogren's syndrome relieved and improved the symptoms of Sjogren's syndrome, and production was also found to be inhibited. In addition, as a result of analyzing the expression change of PAX3 during Sjogren's onset in in vitro experiments and Sjogren's patient samples, it was confirmed that the expression of PAX3 is reduced when the Sjogren's syndrome environment is created. PAX3 of the present invention is a novel therapeutic target for Sjogren's syndrome. It was found that PAX3 and PAX3 expression and activity promoters have the effect of effectively preventing and treating Sjogren's syndrome.